2 Pharma Stocks to Watch: Pfizer, Teva Pharmaceutical

Group 1 - Pfizer Inc (PFE) has provided a 2025 profit outlook that exceeds expectations, contributing to a positive market response [1] - Teva Pharmaceutical Industries Ltd (TEVA) has achieved a significant milestone with its drug in collaboration with Sanofi, successfully meeting the main goal of a mid-stage trial for treating Crohn's disease and ulcerative colitis [1] - PFE's stock is currently up 3.7% at $26.18, while TEVA's stock has surged 20% to $19.80, marking its highest level since February 2019 [2] Group 2 - PFE's stock has a year-to-date deficit of 12.9%, while TEVA boasts an impressive 89.2% year-to-date gain [2] - Options trading for PFE has seen 38,000 calls traded, which is double the typical volume, with the December 12.50 call being the most active [3] - TEVA's options volume is running at 19 times the intraday average, with the December 20 put leading the activity [3]